세계의 과민성대장증후군 치료 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)

Global Irritable Bowel Syndrome Treatment Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033

US $ 3,920 ￦ 5,555,000

PDF & Excel (Single User License)

PDF 및 Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 4,730 ￦ 6,702,000

PDF & Excel (10-user License)

PDF 및 Excel 보고서를 동일 기업 내 10명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

US $ 7,430 ￦ 10,529,000

PDF & Excel (Corporate User License)

PDF 및 Excel 보고서를 동일 기업 내 모든 사용자가 이용할 수 있는 라이선스입니다. 텍스트의 Copy & Paste 가능합니다. 인쇄 가능하며 인쇄물의 이용 범위는 전자파일의 이용 범위와 동일합니다.

한글목차

세계의 과민성대장증후군 치료 시장은 2024년 42억 1,000만 달러에서 2033년에는 94억 달러에 달하고, 상당한 성장을 이룰 전망입니다. 2025년부터 2033년까지 연평균 성장률(CAGR)은 9.34%에 달할 것으로 예측됩니다.

과민성대장증후군(IBS) 치료 시장은 장뇌축과 장내 미생물 군집의 역할이 위장 건강에 미치는 영향에 대한 이해의 진전에 따라 성장하고 있습니다. 표적 프로바이오틱스, 신경조절제, 담즙산 조절제 등 새로운 치료제는 기존의 대증요법에서 벗어나 치료 선택의 폭을 넓히고 있습니다. 향후 유전자, 마이크로바이옴, 대사체 데이터를 활용하여 치료법의 선택과 효과를 최적화하는 맞춤형 의료 전략이 주목받고 있습니다.

또한, 디지털 헬스 플랫폼과 원격의료는 환자의 참여와 모니터링을 강화하고, 적시에 개입과 순응을 촉진하며, 디지털 헬스 플랫폼과 원격의료를 통해 환자 참여와 모니터링을 강화합니다. 치료 요법에 식이 관리 도구와 행동 요법을 통합하는 것이 각광을 받고 있습니다. 비침습적 바이오마커의 발달과 함께 인지도와 진단율의 향상으로 환자층이 확대되고 있습니다. 연구가 진행됨에 따라 IBS 치료 시장은 혁신을 거듭하며 삶의 질을 향상시키는 포괄적이고 환자 중심의 솔루션을 제공할 것입니다.

목차

제1장 서문

제2장 주요 요약

• 시장 하이라이트
• 세계 시장 현황

제3장 과민성대장증후군 치료 - 산업 분석

• 소개 : 시장 역학
• 시장 성장 촉진요인
• 시장 성장 억제요인
• 시장 기회
• 업계 동향
• Porter's Five Forces 분석
• 시장 매력 분석

제4장 밸류체인 분석

• 밸류체인 분석
• 원재료 분석
  • 원재료 리스트
  • 원재료 제조업체 리스트
  • 주요 원재료 가격 동향
• 잠재적 바이어 리스트
• 마케팅 채널
  • 직접 마케팅
  • 간접 마케팅
  • 마케팅 채널 발전 동향

제5장 과민성대장증후군 치료 세계 시장 분석 : 유형별

• 유형별 개요
• 유형별, 과거 및 예측 데이터 분석
• IBS-C
• IBS-D

제6장 과민성대장증후군 치료 세계 시장 분석 : 약물 종류별

• 약물 종류별 개요
• 약물 종류별, 과거 및 예측 데이터 분석
• Xifaxan
• Linzess/Constella
• Viberzi
• Amitiza
• 기타

제7장 과민성대장증후군 치료 세계 시장 분석 : 유통 채널별

• 유통 채널별 개요
• 유통 채널별, 과거 및 예측 데이터 분석
• 병원 약국
• 소매 약국
• 기타

제8장 과민성대장증후군 치료 세계 시장 분석 : 지역별

• 지역별 전망
• 소개
• 북미 매출 분석
  • 개요, 실적과 예측
  • 북미 : 부문별
  • 북미 국가별
  • 미국
  • 캐나다
  • 멕시코
• 유럽 매출 분석
  • 개요, 실적과 예측
  • 유럽 : 부문별
  • 유럽 국가별
  • 영국
  • 프랑스
  • 독일
  • 이탈리아
  • 러시아
  • 기타 유럽
• 아시아태평양 매출 분석
  • 개요, 실적과 예측
  • 아시아태평양 : 부문별
  • 아시아태평양 국가별
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주
  • 동남아시아
  • 기타 아시아태평양
• 라틴아메리카 매출 분석
  • 개요, 실적과 예측
  • 라틴아메리카 : 부문별
  • 라틴아메리카 국가별
  • 브라질
  • 아르헨티나
  • 페루
  • 칠레
  • 기타 라틴아메리카
• 중동 및 아프리카 매출 분석
  • 개요, 실적과 예측
  • 중동 및 아프리카 : 부문별
  • 중동 및 아프리카 국가별 리스트
  • 사우디아라비아
  • 아랍에미리트
  • 이스라엘
  • 남아프리카공화국
  • 기타 중동 및 아프리카

제9장 과민성대장증후군 치료제 기업 경쟁 구도

• 과민성대장증후군 치료 시장 경쟁
• 제휴, 협력, 합의
• 인수합병
• 신제품 출시
• 기타 개발

제10장 기업 개요

• 상위 기업의 시장 점유율 분석
• 시장 집중도
• Ironwood Pharmaceuticals Inc.
• Allergan
• Astellas Pharma Inc.
• Takeda Pharmaceutical Company Limited
• AstraZeneca
• Sanofi S.A.
• Sebela Pharmaceuticals Inc.
• Bausch Health
• Synthetic Biologics Inc.
• Ardelyx

KSM

영문 목차

영문목차

Global Irritable Bowel Syndrome Treatment Market is poised to witness substantial growth, reaching a value of USD 9.4 Billion by the year 2033, up from USD 4.21 Billion attained in 2024. The market is anticipated to display a Compound Annual Growth Rate (CAGR) of 9.34% between 2025 and 2033.

The irritable bowel syndrome (IBS) treatment market is experiencing growth driven by advances in understanding the gut-brain axis and microbiome's role in gastrointestinal health. Novel therapeutics, including targeted probiotics, neuromodulators, and bile acid modulators, are expanding treatment options beyond traditional symptom management. Future developments will focus on personalized medicine strategies leveraging genetic, microbiome, and metabolomic data to optimize therapy selection and efficacy.

Moreover, digital health platforms and telemedicine are enhancing patient engagement and monitoring, facilitating timely intervention and adherence. The integration of dietary management tools and behavioral therapies within treatment regimens is gaining prominence. Increasing awareness and diagnosis rates, coupled with the development of non-invasive biomarkers, are broadening the patient pool. As research advances, the IBS treatment market will continue to innovate, offering comprehensive, patient-centric solutions that improve quality of life.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

LIST OF SEGMENTS COVERED

This section of the Irritable Bowel Syndrome Treatment market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

• IBS-C
• IBS-D

By Drug Class

• Xifaxan
• Linzess/Constella
• Viberzi
• Amitiza
• Others

By Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Others
• List of Companies Profiled in the report
• Ironwood Pharmaceuticals Inc., Allergan, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, AstraZeneca, Sanofi S.A., Sebela Pharmaceuticals Inc., Bausch Health, Synthetic Biologics Inc., Ardelyx.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

TABLE OF CONTENTS

1. PREFACE

• 1.1. Report Description
  • 1.1.1 Objective
  • 1.1.2 Target Audience
  • 1.1.3 Unique Selling Proposition (USP) & offerings
• 1.2. Research Scope
• 1.3. Research Methodology
  • 1.3.1 Market Research Process
  • 1.3.2 Market Research Methodology

2. EXECUTIVE SUMMARY

• 2.1. Highlights of Market
• 2.2. Global Market Snapshot

3. IRRITABLE BOWEL SYNDROME TREATMENT - INDUSTRY ANALYSIS

• 3.1. Introduction - Market Dynamics
• 3.2. Market Drivers
• 3.3. Market Restraints
• 3.4. Opportunities
• 3.5. Industry Trends
• 3.6. Porter's Five Force Analysis
• 3.7. Market Attractiveness Analysis
  • 3.7.1 Market Attractiveness Analysis By Type
  • 3.7.2 Market Attractiveness Analysis By Drug Class
  • 3.7.3 Market Attractiveness Analysis By Distribution Channel
  • 3.7.4 Market Attractiveness Analysis By Regions

4. VALUE CHAIN ANALYSIS

• 4.1. Value Chain Analysis
• 4.2. Raw Material Analysis
  • 4.2.1 List of Raw Materials
  • 4.2.2 Raw Material Manufactures List
  • 4.2.3 Price Trend of Key Raw Materials
• 4.3. List of Potential Buyers
• 4.4. Marketing Channel
  • 4.4.1 Direct Marketing
  • 4.4.2 Indirect Marketing
  • 4.4.3 Marketing Channel Development Trend

5. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET ANALYSIS BY TYPE

• 5.1. Overview By Type
• 5.2. Historical and Forecast Data Analysis By Type
• 5.3. IBS-C Historic and Forecast Sales By Regions
• 5.4. IBS-D Historic and Forecast Sales By Regions

6. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET ANALYSIS BY DRUG CLASS

• 6.1. Overview By Drug Class
• 6.2. Historical and Forecast Data Analysis By Drug Class
• 6.3. Xifaxan Historic and Forecast Sales By Regions
• 6.4. Linzess/Constella Historic and Forecast Sales By Regions
• 6.5. Viberzi Historic and Forecast Sales By Regions
• 6.6. Amitiza Historic and Forecast Sales By Regions
• 6.7. Others Historic and Forecast Sales By Regions

7. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET ANALYSIS BY DISTRIBUTION CHANNEL

• 7.1. Overview By Distribution Channel
• 7.2. Historical and Forecast Data Analysis By Distribution Channel
• 7.3. Hospital Pharmacy Historic and Forecast Sales By Regions
• 7.4. Retail Pharmacy Historic and Forecast Sales By Regions
• 7.5. Others Historic and Forecast Sales By Regions

8. GLOBAL IRRITABLE BOWEL SYNDROME TREATMENT MARKET ANALYSIS BY GEOGRAPHY

• 8.1. Regional Outlook
• 8.2. Introduction
• 8.3. North America Sales Analysis
  • 8.3.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.3.2 North America By Segment Sales Analysis
  • 8.3.3 North America By Country Sales Analysis
  • 8.3.4 United States Sales Analysis
  • 8.3.5 Canada Sales Analysis
  • 8.3.6 Mexico Sales Analysis
• 8.4. Europe Sales Analysis
  • 8.4.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.4.2 Europe By Segment Sales Analysis
  • 8.4.3 Europe By Country Sales Analysis
  • 8.4.4 United Kingdom Sales Analysis
  • 8.4.5 France Sales Analysis
  • 8.4.6 Germany Sales Analysis
  • 8.4.7 Italy Sales Analysis
  • 8.4.8 Russia Sales Analysis
  • 8.4.9 Rest Of Europe Sales Analysis
• 8.5. Asia Pacific Sales Analysis
  • 8.5.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.5.2 Asia Pacific By Segment Sales Analysis
  • 8.5.3 Asia Pacific By Country Sales Analysis
  • 8.5.4 China Sales Analysis
  • 8.5.5 India Sales Analysis
  • 8.5.6 Japan Sales Analysis
  • 8.5.7 South Korea Sales Analysis
  • 8.5.8 Australia Sales Analysis
  • 8.5.9 South East Asia Sales Analysis
  • 8.5.10 Rest Of Asia Pacific Sales Analysis
• 8.6. Latin America Sales Analysis
  • 8.6.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.6.2 Latin America By Segment Sales Analysis
  • 8.6.3 Latin America By Country Sales Analysis
  • 8.6.4 Brazil Sales Analysis
  • 8.6.5 Argentina Sales Analysis
  • 8.6.6 Peru Sales Analysis
  • 8.6.7 Chile Sales Analysis
  • 8.6.8 Rest of Latin America Sales Analysis
• 8.7. Middle East & Africa Sales Analysis
  • 8.7.1 Overview, Historic and Forecast Data Sales Analysis
  • 8.7.2 Middle East & Africa By Segment Sales Analysis
  • 8.7.3 Middle East & Africa By Country Sales Analysis
  • 8.7.4 Saudi Arabia Sales Analysis
  • 8.7.5 UAE Sales Analysis
  • 8.7.6 Israel Sales Analysis
  • 8.7.7 South Africa Sales Analysis
  • 8.7.8 Rest Of Middle East And Africa Sales Analysis

9. COMPETITIVE LANDSCAPE OF THE IRRITABLE BOWEL SYNDROME TREATMENT COMPANIES

• 9.1. Irritable Bowel Syndrome Treatment Market Competition
• 9.2. Partnership/Collaboration/Agreement
• 9.3. Merger And Acquisitions
• 9.4. New Product Launch
• 9.5. Other Developments

10. COMPANY PROFILES OF IRRITABLE BOWEL SYNDROME TREATMENT INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Market Concentration Rate
• 10.3. Ironwood Pharmaceuticals Inc.
  • 10.3.1 Company Overview
  • 10.3.2 Company Revenue
  • 10.3.3 Products
  • 10.3.4 Recent Developments
• 10.4. Allergan
  • 10.4.1 Company Overview
  • 10.4.2 Company Revenue
  • 10.4.3 Products
  • 10.4.4 Recent Developments
• 10.5. Astellas Pharma Inc.
  • 10.5.1 Company Overview
  • 10.5.2 Company Revenue
  • 10.5.3 Products
  • 10.5.4 Recent Developments
• 10.6. Takeda Pharmaceutical Company Limited
  • 10.6.1 Company Overview
  • 10.6.2 Company Revenue
  • 10.6.3 Products
  • 10.6.4 Recent Developments
• 10.7. AstraZeneca
  • 10.7.1 Company Overview
  • 10.7.2 Company Revenue
  • 10.7.3 Products
  • 10.7.4 Recent Developments
• 10.8. Sanofi S.A.
  • 10.8.1 Company Overview
  • 10.8.2 Company Revenue
  • 10.8.3 Products
  • 10.8.4 Recent Developments
• 10.9. Sebela Pharmaceuticals Inc.
  • 10.9.1 Company Overview
  • 10.9.2 Company Revenue
  • 10.9.3 Products
  • 10.9.4 Recent Developments
• 10.10. Bausch Health
  • 10.10.1 Company Overview
  • 10.10.2 Company Revenue
  • 10.10.3 Products
  • 10.10.4 Recent Developments
• 10.11. Synthetic Biologics Inc.
  • 10.11.1 Company Overview
  • 10.11.2 Company Revenue
  • 10.11.3 Products
  • 10.11.4 Recent Developments
• 10.12. Ardelyx
  • 10.12.1 Company Overview
  • 10.12.2 Company Revenue
  • 10.12.3 Products
  • 10.12.4 Recent Developments

Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies

관련자료